Ken Griffin Prothena Corp Public LTD CO Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$16.73 - $24.79 $70,266 - $104,118	4,200 Added 25.15%	20,900 $349,000
Q2 2024 Aug 14, 2024	SELL	$19.54 - $26.15 $119,194 - $159,515	-6,100 Reduced 26.75%	16,700 $344,000
Q1 2024 May 15, 2024	SELL	$24.75 - $40.66 $279,675 - $459,457	-11,300 Reduced 33.14%	22,800 $564,000
Q4 2023 Feb 14, 2024	BUY	$32.31 - $52.32 $126,009 - $204,048	3,900 Added 12.91%	34,100 $1.24 Million
Q3 2023 Nov 14, 2023	BUY	$47.3 - $70.6 $274,340 - $409,479	5,800 Added 23.77%	30,200 $1.46 Million
Q2 2023 Aug 14, 2023	BUY	$48.26 - $78.59 $270,256 - $440,104	5,600 Added 29.79%	24,400 $1.67 Million
Q1 2023 May 15, 2023	SELL	$46.97 - $58.27 $399,245 - $495,295	-8,500 Reduced 31.14%	18,800 $911,000
Q4 2022 Feb 14, 2023	SELL	$52.05 - $65.0 $4.96 Million - $6.19 Million	-95,300 Reduced 77.73%	27,300 $1.64 Million
Q3 2022 Nov 14, 2022	BUY	$25.16 - $60.63 $1.94 Million - $4.69 Million	77,300 Added 170.64%	122,600 $7.43 Million

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $685M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.